Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study

被引：0

作者：

Kabbaha, Suad ^{[1
]}

Dempsey, Sarah Carder ^{[1
]}

Thorlund, Kristian ^{[1
]}

机构：

[1] BioSpark AI Technol, Vancouver, BC, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20092

引用

页数：1

共 50 条

[31] Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer
Pan, Yingying
Gao, Guanghui
Chen, Xiaoxia
Tian, Qinrui
Wu, Fengying
Liu, Qian
Wang, Yan
Jiang, Tao
Liu, Yiwei
Li, Xuefei
Yang, Shuo
Xu, Chuan
Su, Chunxia
Zhou, Fei
Ren, Shengxiang
Zhou, Caicun
THORACIC CANCER, 2019, 10 (04) : 686 - 694
[32] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
Kim, Tae Min
Girard, Nicolas
Low, Grace Kah Mun
Zhuo, Jianmin
Yu, Dae Young
Yang, Yishen
Murota, Maiko
Lim, Cindy Thiow Koon
Kleinman, Nora J.
Cho, Byoung Chul
ACTA ONCOLOGICA, 2023, : 1689 - 1697
[33] Clinical characteristics and real-world progression-free survival of patients with EGFR mutation positive non-small cell lung cancer treated with afatinib as first-line: A retrospective cohort study from Indonesia
Soeroso, N. N.
Syahruddin, E.
ANNALS OF ONCOLOGY, 2022, 33 : S1555 - S1556
[34] Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
Azuma, Koichi
Komatsu, Nobukazu
Hattori, Satoshi
Matsueda, Satoko
Kawahara, Akihiko
Sasada, Tetsuro
Itoh, Kyogo
Hoshino, Tomoaki
PLOS ONE, 2014, 9 (01):
[35] Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations
Winfree, Katherine B.
Molife, Cliff
Peterson, Patrick M.
Chen, Yongmei
Visseren-Grul, Carla M.
Leusch, Mark S.
Beyrer, Julie
Dimou, Anastasios
FUTURE ONCOLOGY, 2021, 17 (22) : 2867 - 2881
[36] Real World data of Advanced Non-Small Cell Lung Cancer Patients EGFR Mutated from a Peruvian Cohort
Galvez-Nino, M.
Ruiz, R.
Lozano, S.
Roque, K.
Coanqui, O.
Valdivieso, N.
Olivera, M.
Mas, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S990 - S990
[37] Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases
Yu, Xiaoqing
Sheng, Jiamin
Pan, Guoqiang
Fan, Yun
INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (05) : 1121 - 1128
[38] Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Lee, Chee Khoon
Brown, Chris
Gralla, Richard J.
Hirsh, Vera
Thongprasert, Sumitra
Tsai, Chun-Ming
Tan, Eng Huat
Ho, James Chung-Man
Chu, Da Tong
Zaatar, Adel
Osorio Sanchez, Jemela Anne
Vu Van Vu
Au, Joseph Siu Kie
Inoue, Akira
Lee, Siow Ming
Gebski, Val
Yang, James Chih-Hsin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (09): : 595 - 605
[39] Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib
Teranishi, Shuhei
Sugimoto, Chihiro
Nagaoka, Satoshi
Nagayama, Hirokazu
Segawa, Wataru
Miyasaka, Atsushi
Hiro, Shuntaro
Kajita, Yukihito
Maeda, Chihiro
Kobayashi, Nobuaki
Yamamoto, Masaki
Kudo, Makoto
Kaneko, Takeshi
THORACIC CANCER, 2022, 13 (19) : 2741 - 2750
[40] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Gao, X.
Wei, X-W.
Wu, Y-L.
Zhou, Q.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →